FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulation
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Sphingosine 1-phosphate (S1P), a lysophospholipid, has gained relevance to multiple sclerosis through the discovery of FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis. Its mechanism of action is thought to be immunological through an active phosphorylated metabolite, FTY720-P, that resembles S1P and alters lymphocyte trafficking through receptor subtype S1P 1 . However, previously reported expression and in vitro studies of S1P receptors suggested that direct CNS effects of FTY720 might theoretically occur through receptor modulation on neurons and glia. To identify CNS cells functionally contributing to FTY720 activity, genetic approaches were combined with cellular and molecular analyses. These studies relied on the functional assessment, based on clinical score, of conditional null mouse mutants lacking S1P 1 in CNS cell lineages and challenged by experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. All conditional null mutants displayed WT lymphocyte trafficking that responded normally to FTY720. In marked contrast, EAE was attenuated and FTY720 efficacy was lost in CNS mutants lacking S1P 1 on GFAP-expressing astrocytes but not on neurons. In situ hybridization studies confirmed that astrocyte loss of S1P 1 was the key alteration in functionally affected mutants. Reductions in EAE clinical scores were paralleled by reductions in demyelination, axonal loss, and astrogliosis. Receptor rescue and pharmacological experiments supported the loss of S1P 1 on astrocytes through functional antagonism by FTY720-P as a primary FTY720 mechanism. These data identify nonimmunological CNS mechanisms of FTY720 efficacy and implicate S1P signaling pathways within the CNS as targets for multiple sclerosis therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety
Tronche, F., Kellendonk, C., Kretz, O., Gass, P., Anlag, K., Orban, P. C., Bock, R., Klein, R., & Schütz, G. (1999) · Nature Genetics · doi:10.1038/12703 · Cited by 1,838
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Palay, S. L., & Chan-Palay, V. (1974) · Springer eBooks · doi:10.1007/978-3-642-65581-4 · Cited by 1,506
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence
Bignami, A., Eng, L. F., Dahl, D., & Uyeda, C. T. (1972) · Brain Research · doi:10.1016/0006-8993(72)90398-8 · Cited by 1,455
Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System
Steinman, M. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81107-1 · Cited by 903
Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate
Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., Xu, Y., Camerer, E., Zheng, Y.-W., Huang, Y., Cyster, J. G., et al. (2007) · Science · doi:10.1126/science.1139221 · Cited by 877
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Self-citationLymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients
Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y., & Cyster, J. G. (2005) · Science · doi:10.1126/science.1113640 · Cited by 787
Lysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
Self-citationMalatesta, P., Hack, M. A., Hartfuss, E., Kettenmann, H., Klinkert, W., Kirchhoff, F., & Götz, M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00116-8 · Cited by 746
Finding a way out: lymphocyte egress from lymphoid organs
Schwab, S. R., & Cyster, J. G. (2007) · Nature Immunology · doi:10.1038/ni1545 · Cited by 605
Zhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., Marth, J. D., & Parada, L. F. (2001) · Genes & Development · doi:10.1101/gad.862101 · Cited by 604
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets
Han, M. H., Hwang, S.-I., Roy, D. B., Lundgren, D. H., Price, J. V., Ousman, S. S., Fernald, G. H., Gerlitz, B., Robinson, W. H., Baranzini, S. E., et al. (2008) · Nature · doi:10.1038/nature06559 · Cited by 516
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis
Ishii, M., Egen, J. G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y., Vacher, J., Proia, R. L., & Germain, R. N. (2009) · Nature · doi:10.1038/nature07713 · Cited by 515 · cited 1×
“FTY720 is phosphorylated in vivo to produce the activemetabolite FTY720-P, which is a nonselective S1P receptor agonist for four of the five known S1P receptors (4–6), and can function as an agonist in vivo (7).”
BackgroundOo, M. L., Thangada, S., Wu, M.-T., Liu, C. H., Macdonald, T. L., Lynch, K. R., Lin, C.-Y., & Hla, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610318200 · Cited by 405
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
Signaling between glia and neurons: focus on synaptic plasticity
Allen, N. J., & Barres, B. A. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.08.006 · Cited by 323
Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., & Billich, A. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127183 · Cited by 322
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
Malmeström, C., Haghighi, S., Rosengren, L., Andersen, O., & Lycke, J. (2003) · Neurology · doi:10.1212/01.wnl.0000098880.19793.b6 · Cited by 318
Astrocytes in multiple sclerosis: A product of their environment
Nair, A., Frederick, T. J., & Miller, S. D. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8059-5 · Cited by 313
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2
Paugh, S. W., Payne, S. G., Barbour, S. E., Milstien, S., & Spiegel, S. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01168-2 · Cited by 302
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Webb, M., Tham, C.-S., Lin, F.-F., Lariosa-Willingham, K., Yu, N., Hale, J., Mandala, S., Chun, J., & Rao, T. S. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.04.015 · Cited by 226
Self-citationTedesco-Silva, H., Mourad, G., Kahan, B. D., Boira, J. G., Weimar, W., Mulgaonkar, S., Nashan, B., Madsen, S., Charpentier, B., Pellet, P., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000121761.02129.a6 · Cited by 215
Sorensen, S. D., Nicole, O., Peavy, R. D., Montoya, L. M., Lee, C. J., Murphy, T. J., Traynelis, S. F., & Hepler, J. R. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1199 · Cited by 210
Self-citationA crucial role for Olig2 in white matter astrocyte development
Cai, J., Chen, Y., Cai, W.-H., Hurlock, E. C., Wu, H., Kernie, S. G., Parada, L. F., & Lu, Q. R. (2007) · Development · doi:10.1242/dev.02847 · Cited by 203 · cited 2×
“S1) generated conditionally null mutants after crosses with previously established transgenic mice expressing different cell lineage promoters driving Cre recombinase for all CNS lineages (NestinCre) (23), neurons (Synapsin-Cre) (24), or GFAP-expressing cell lineages, particularly in spinal cord white matter astrocyte…”
BackgroundMethodKimura, A., Ohmori, T., Ohkawa, R., Madoiwa, S., Mimuro, J., Murakami, T., Kobayashi, E., Hoshino, Y., Yatomi, Y., & Sakata, Y. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0223 · Cited by 202
Sphingosine 1‐phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions
Van Doorn, R., Van Horssen, J., Verzijl, D., Witte, M., Ronken, E., Van Het Hof, B., Lakeman, K., Dijkstra, C. D., Van Der Valk, P., Reijerkerk, A., et al. (2010) · Glia · doi:10.1002/glia.21021 · Cited by 201
Wheeler, D., Bandaru, V. V. R., Calabresi, P. A., Nath, A., & Haughey, N. J. (2008) · Brain · doi:10.1093/brain/awn190 · Cited by 171
Astrocyte characterization in the multiple sclerosis glial scar
Holley, J. E., Gveric, D., Newcombe, J., Cuzner, M. L., & Gutowski, N. J. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00491.x · Cited by 169
FTY720: ALTERED LYMPHOCYTE TRAFFIC RESULTS IN ALLOGRAFT PROTECTION
Brinkmann, V., Pinschewer, D. D., Feng, L., & Chen, S. (2001) · Transplantation · doi:10.1097/00007890-200109150-00002 · Cited by 169
Central nervous system-directed effects of FTY720 (fingolimod)
Miron, V. E., Schubart, A., & Antel, J. P. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.031 · Cited by 164
Pan, S., Mi, Y., Pally, C., Beerli, C., Chen, A. P., Guerini, D., Hinterding, K., Nuesslein‐Hildesheim, B., Tuntland, T., Lefebvre, S., et al. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.017 · Cited by 129
Yu, N., Lariosa-Willingham, K. D., Lin, F., Webb, M., & Rao, T. S. (2003) · Glia · doi:10.1002/glia.10297 · Cited by 124
Tani, M., Glabinski, A. R., Tuohy, V. K., Stoler, M. H., Estes, M. L., & Ransohoff, R. M. (1996) · Europe PMC (PubMed Central) · Cited by 123
Microglial activation state and lysophospholipid acid receptor expression
Tham, C., Lin, F., Rao, T. S., Yu, N., & Webb, M. (2003) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2003.09.003 · Cited by 119
Luo, J., Ho, P. P., Buckwalter, M. S., Hsu, T., Lee, L. Y., Zhang, H., Kim, D.-K., Kim, S.-J., Gambhir, S. S., Steinman, L., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31763 · Cited by 115
Wu, Y.-P., Mizugishi, K., Bektas, M., Sandhoff, R., & Proia, R. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn126 · Cited by 96
The Mouse Gene for the Inducible G-Protein-Coupled Receptoredg-1
Liu, C. H., & Hla, T. (1997) · Genomics · doi:10.1006/geno.1997.4759 · Cited by 73
Cited by
Sphingolipid metabolites in inflammatory disease
Maceyka, M., & Spiegel, S. (2014) · Nature · doi:10.1038/nature13475 · Cited by 1,277
Astrocyte Crosstalk in CNS Inflammation
Linnerbauer, M., Wheeler, M. A., & Quintana, F. J. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.012 · Cited by 989
“Interestingly, astrocytes upregulate the expression of the sphingolipid receptor S1PR1 upon activation, and conditional ablation of S1PR1 in astrocytes results in diminished EAE severity and increased neuronal survival (Choi et al., 2011).”
BackgroundIntegrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
Lake, B. B., Chen, S., Sos, B. C., Fan, J., Kaeser, G. E., Yung, Y. C., Duong, T. E., Gao, D., Chun, J., Kharchenko, P. V., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4038 · Cited by 983
Self-citationAstrocytes: Key Regulators of Neuroinflammation
Colombo, E., & Farina, C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.06.006 · Cited by 904
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Metadata
- Authors
- Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., & Chun, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-12-21
- Volume
- 108
- Issue
- 2
- Pages
- 751-756
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2102478723
- Cited by
- 581
- References
- 46
- FWCI
- 21.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.